

Pedro Pablo Medina Vico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6144716/publications.pdf>

Version: 2024-02-01

52
papers

3,619
citations

279798

23
h-index

254184

43
g-index

55
all docs

55
docs citations

55
times ranked

6205
citing authors

#	ARTICLE	IF	CITATIONS
1	OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. <i>Nature</i> , 2010, 467, 86-90.	27.8	877
2	Regression of murine lung tumors by the let-7 microRNA. <i>Oncogene</i> , 2010, 29, 1580-1587.	5.9	465
3	MicroRNAs and cancer: An overview. <i>Cell Cycle</i> , 2008, 7, 2485-2492.	2.6	325
4	FGF Regulates TGF- β 2 Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA Expression. <i>Cell Reports</i> , 2012, 2, 1684-1696.	6.4	265
5	Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. <i>Human Mutation</i> , 2008, 29, 617-622.	2.5	226
6	DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 4333-4339.	1.6	132
7	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. <i>Oncogene</i> , 2007, 26, 1616-1625.	5.9	130
8	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. <i>Oncogene</i> , 2004, 23, 4037-4040.	5.9	111
9	Genetic and Epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 170-177.	2.8	103
10	The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. <i>Human Molecular Genetics</i> , 2009, 18, 1343-1352.	2.9	99
11	Expression signatures in lung cancer reveal a profile for EGFR mutant tumours and identify selective PIK3CA overexpression by gene amplification. <i>Journal of Pathology</i> , 2008, 214, 347-356.	4.5	92
12	Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. <i>Epigenetics</i> , 2008, 3, 64-68.	2.7	92
13	Maslinic acid, a triterpenic anti-tumoural agent, interferes with cytoskeleton protein expression in HT29 human colon-cancer cells. <i>Journal of Proteomics</i> , 2013, 83, 15-25.	2.4	64
14	Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. <i>Oncogene</i> , 2004, 23, 5084-5091.	5.9	61
15	Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. <i>Human Molecular Genetics</i> , 2005, 14, 973-982.	2.9	55
16	Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives. <i>Current Organic Chemistry</i> , 2015, 19, 919-947.	1.6	53
17	Maslinic Acid, a Natural Triterpene, Induces a Death Receptor-Mediated Apoptotic Mechanism in Caco-2 p53-Deficient Colon Adenocarcinoma Cells. <i>PLoS ONE</i> , 2016, 11, e0146178.	2.5	43
18	Antitumour activity on extrinsic apoptotic targets of the triterpenoid maslinic acid in p53-deficient Caco-2 adenocarcinoma cells. <i>Biochimie</i> , 2013, 95, 2157-2167.	2.6	37

#	ARTICLE	IF	CITATIONS
19	Gene amplification of the transcription factor DP1 and <i>CTNND1</i> in human lung cancer. <i>Journal of Pathology</i> , 2010, 222, 89-98.	4.5	33
20	Maslinic Acid, a Triterpene from Olive, Affects the Antioxidant and Mitochondrial Status of B16F10 Melanoma Cells Grown under Stressful Conditions. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-11.	1.2	33
21	Inhibiting microRNA function in vivo. <i>Nature Methods</i> , 2009, 6, 37-38.	19.0	31
22	Target molecules in 3T3-L1 adipocytes differentiation are regulated by maslinic acid, a natural triterpene from <i>Olea europaea</i> . <i>Phytomedicine</i> , 2016, 23, 1301-1311.	5.3	27
23	Expression inactivation of SMARCA4 by microRNAs in lung tumors. <i>Human Molecular Genetics</i> , 2015, 24, 1400-1409.	2.9	26
24	Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. <i>Leukemia</i> , 2020, 34, 2722-2735.	7.2	24
25	The oleanolic acid derivative, 3-O-succinyl-28-O-benzyl oleanolate, induces apoptosis in B16F10 melanoma cells via the mitochondrial apoptotic pathway. <i>RSC Advances</i> , 2016, 6, 93590-93601.	3.6	23
26	SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. <i>Nature Communications</i> , 2021, 12, 4319.	12.8	22
27	Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2019, 9, 93.	6.2	20
28	SWI/SNF proteins as targets in cancer therapy. <i>Journal of Hematology and Oncology</i> , 2014, 7, 81.	17.0	17
29	Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer. <i>Oncogene</i> , 2020, 39, 5479-5493.	5.9	13
30	The value of lncRNA FENDRR and FOXF1 as a prognostic factor for survival of lung adenocarcinoma. <i>Oncotarget</i> , 2020, 11, 1172-1185.	1.8	12
31	Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency. <i>PLoS ONE</i> , 2021, 16, e0252848.	2.5	12
32	BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines. <i>Clinical and Translational Oncology</i> , 2017, 19, 1010-1017.	2.4	11
33	The value of desmosomal plaque-related markers to distinguish squamous cell carcinoma and adenocarcinoma of the lung. <i>Uppsala Journal of Medical Sciences</i> , 2020, 125, 19-29.	0.9	11
34	Microarray Profiling of Mononuclear Peripheral Blood Cells Identifies Novel Candidate Genes Related to Chemoradiation Response in Rectal Cancer. <i>PLoS ONE</i> , 2013, 8, e74034.	2.5	10
35	Preoperative chemoradiotherapy for rectal cancer: the sensitizer role of the association between miR-375 and c-Myc. <i>Oncotarget</i> , 2017, 8, 82294-82302.	1.8	8
36	LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma. <i>Cancers</i> , 2020, 12, 2080.	3.7	7

#	ARTICLE	IF	CITATIONS
37	LncRNA-mRNA Co-Expression Analysis Identifies AL133346.1/CCN2 as Biomarkers in Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2020, 12, 3803.	3.7	7
38	Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes. <i>Blood</i> , 2022, 139, 2406-2410.	1.4	7
39	Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models. <i>Cancers</i> , 2020, 12, 3712.	3.7	6
40	Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma. <i>Clinical Epigenetics</i> , 2022, 14, 42.	4.1	5
41	PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 323-332.	4.4	4
42	Long Noncoding RNAs as Cancer Biomarkers. , 2018, , 95-114.		3
43	Wiping DNA Methylation: Wip1 Regulates Genomic Fluidity on Cancer. <i>Cancer Cell</i> , 2013, 24, 405-407.	16.8	2
44	The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma. <i>Human Molecular Genetics</i> , 2021, 30, 2263-2271.	2.9	2
45	SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a,) Tj ETQq1 1 0,784314 rgBT /Ove 0,1		
46	P2.02-010 Oncogenic Role of PKP1 in Non-Small-Cell Lung Cancer.. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2101-S2102.	1.1	0
47	MA17.06 Plakophilin 1 Enhances MYC Expression, Promoting Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S319.	1.1	0
48	P1.03-20 Exploring Driver Mutations in Non-Coding RNAs in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S425.	1.1	0
49	EP1.14-36 Suicide Gene Therapy Directed by MicroRNA Activity. <i>Journal of Thoracic Oncology</i> , 2019, 14, S1046.	1.1	0
50	Abstract 5052: Pro-oncogenic role of desmosomal plaque-related proteins in non-small cell lung cancer (NSCLC). , 2016, , .		0
51	Abstract 4479: Unveiling the relationship between the SWI/SNF chromatin remodeling complex and noncoding RNAs. , 2016, , .		0
52	Opportunities of miRNAs in cancer therapeutics. , 2022, , 153-164.		0